Clinical trials: Bendamustine
Chronic Lymphocytic Leukemia (CLL), Leukaemia, Lymphocytic, Chronic
Ofatumumab Plus Bendamustine in Frontline and Relapsed Chronic Lymphocytic Leukaemia (CLL)
This is a Phase II, open label, single arm, multi-centre study investigating the safety and efficacy of ofatumumab plus bendamustine in subjects with untreated or relapsed CLL.
- Trial name
- NCT01520922
- Testing
- Ofatumumab, Bendamustine
- Where
- 33 sites in United States, Belgium and 6 more
- Volunteers
- 99 people
- Sponsor
- Novartis Pharmaceuticals
Chronic Lymphocytic Leukemia
A Study of Safety and Effectiveness of Bendamustine Hydrochloride in Adult Filipino Patients With Chronic Lymphocytic Leukemia
The purpose of this study is to assess safety and effectiveness of extended bendamustine in the treatment of chronic lymphocytic leukemia (CLL).
- Trial name
- NCT01739491
- Testing
- No intervention
- Sponsor
- Janssen Pharmaceutica
Cancer Which Has Either Progressed or Relapsed After Standard Therapy, or for Which no Curative or Standard Therapy is Appropriate
A Phase I, Bioequivalence Study to Evaluate Two Formulations of Bendamustine (BDM) Hydrochloride (HCl) Administered to Cancer Patients
The purpose of this study is to demonstrate that a new formulation of an Bendamustine (BDM) Hydrochloride (HCl) is bioequivalent (BE) (similar) to the commercially available product in patients with cancer.
- Trial name
- NCT02162888
- Testing
- Test Product (Bendamustine)
- Where
- 10 sites in United States
- Volunteers
- 81 people
- Sponsor
- Eagle Pharmaceuticals, Inc.
Hodgkin Disease
A Study of Nivolumab Plus Brentuximab Vedotin in Patients Between 5 and 30 Years Old, With Hodgkin's Lymphoma (cHL), Relapsed or Refractory From First Line Treatment
The purpose of this study is to determine whether nivolumab plus brentuximab vedotin (followed by brentuximab vedotin plus bendamustine in patient with suboptimal response) is safe and effective in treating patients with…
- Trial name
- CheckMate 744 (NCT02927769)
- Testing
- Nivolumab, brentuximab vedotin, bendamustine
- Where
- 79 sites in United States, Canada and 9 more
- Volunteers
- 72 people
- Sponsor
- Bristol-Myers Squibb
B-cell Lymphoma
INCB050465 in Combination With Rituximab, Bendamustine and Rituximab, or Ibrutinib in Participants With Previously Treated B-Cell Lymphoma (CITADEL-112)
The purpose of this study is to evaluate the safety and tolerability of parsaclisib when combined with rituximab, bendamustine and rituximab, or ibrutinib in participants with relapsed or refractory B-cell lymphoma.
- Trial name
- NCT03424122
- Testing
- Parsaclisib, Rituximab, Bendamustine
- Where
- 21 sites in United States, Italy and 1 more
- Volunteers
- 50 people
- Sponsor
- Incyte Corporation
Lymphoma, B-Cell
Study to Evaluate Tolerability of Iberdomide (CC-220) in Combination With Polatuzumab Vedotin Plus Rituximab or Tafasitamab or Rituximab Plus Chemotherapy in B-cell Lymphoma
This is a Phase 1b/2 randomized study of Iberdomide (CC-220) added to 3 different combination regimens (polatuzumab vedotin plus rituximab (Cohort A), tafasitamab (Cohort B), rituximab plus gemcitabine and platinum-based…
- Trial name
- NCT04882163
- Testing
- CC-220, Polatuzumab vedotin, Rituximab
- Where
- 27 sites in United States, Austria and 6 more
- Sponsor
- Celgene
Diffuse Large B-Cell Lymphoma, Follicular Lymphoma
Safety and Efficacy Trial of Epcoritamab Combinations in Subjects With B-cell Non-Hodgkin Lymphoma (B-NHL)
The purpose of this trial is to measure the safety and effectiveness of epcoritamab (EPKINLY™), either by itself or together with other therapies, when treating participants with B-cell non-Hodgkin Lymphoma (B-NHL).
- Trial name
- EPCORE™ NHL-2 (NCT04663347)
- Testing
- rituximab, cyclophosphamide, doxorubicin, vincristine, and prednisone, rituximab and lenalidomide, rituximab and bendamustine
- Where
- 57 sites in United States, Australia and 11 more
- Volunteers
- 543 people
- Sponsor
- Genmab
Malignancy, Non-hodgkin Lymphoma
A Phase 1/2 Study of CYT-0851 in B-Cell Malignancies and Advanced Solid Tumors
This clinical trial is an interventional, active-treatment, open-label, multi-center, Phase 1/2 study. The study objectives are to assess the safety, tolerability and pharmacokinetics (PK) of CYT-0851 in patients with…
- Conditions
- Malignancy, Non-hodgkin Lymphoma, Multiple Myeloma, Breast Cancer
- Trial name
- NCT03997968
- Testing
- CYT-0851, CYT-0851 in combination with gemcitabine, CYT-0851 in combination with capecitabine
- Where
- 16 sites in United States
- Volunteers
- 169 people
- Sponsor
- Cyteir Therapeutics, Inc.
Anaplastic Large Cell Lymphoma, Peripheral T Cell Lymphoma
Phase 1 Study of Autologous CD30.CAR-T in Relapsed or Refractory CD30 Positive Non-Hodgkin Lymphoma
This is a phase 1 study to evaluate safety and dose-limiting toxicity of autologous CD30.CAR-T in subjects with relapsed or refractory CD30+ Non-Hodgkin Lymphoma
- Conditions
- Anaplastic Large Cell Lymphoma, Peripheral T Cell Lymphoma, Extranodal NK/T-cell Lymphoma, Diffuse Large B Cell Lymphoma
- Trial name
- CERTAIN (NCT04526834)
- Testing
- CD30.CAR-T
- Where
- 4 sites in United States
- Volunteers
- 21 people
- Sponsor
- Tessa Therapeutics
Multiple Myeloma
Study of Bendamustine Combined With Bortezomib for Patients With Relapsed/Refractory Multiple Myeloma
The primary objective of this study is to assess the safety and tolerability of bendamustine as combination therapy with bortezomib for patients with relapsed/refractory multiple myeloma (MM).
- Trial name
- NCT00920855
- Testing
- bendamustine, bortezomib
- Where
- 13 sites in United States
- Volunteers
- 40 people
- Sponsor
- Cephalon
Follicular Lymphoma
A Study Evaluating the Safety and Efficacy of Venetoclax (GDC-0199) Plus Bendamustine + Rituximab (BR) in Comparison With BR or Venetoclax Plus Rituximab in Participants With Relapsed and Refractory Follicular Non-Hodgkin's Lymphoma (fNHL)
This open-label, international, multicenter study will investigate the safety and efficacy of venetoclax (GDC-0199) in combination with bendamustine plus rituximab (venetoclax + BR) compared with BR alone in participants with…
- Trial name
- NCT02187861
- Testing
- Venetoclax, Bendamustine, Rituximab
- Where
- 71 sites in United States, Australia and 6 more
- Volunteers
- 163 people
- Sponsor
- Hoffmann-La Roche
Non-Hodgkin's Lymphoma
A Study of Obinutuzumab (RO5072759) Plus Chemotherapy in Comparison With Rituximab Plus Chemotherapy Followed by Obinutuzumab or Rituximab Maintenance in Patients With Untreated Advanced Indolent Non-Hodgkin's Lymphoma (GALLIUM)
This open-label, randomized study will assess the efficacy and safety of obinutuzumab (RO5072759) in combination with chemotherapy compared to rituximab (MabThera/Rituxan) with chemotherapy followed by obinutuzumab or rituximab…
- Trial name
- NCT01332968
- Testing
- Obinutuzumab, Cyclophosphamide, Doxorubicin
- Where
- 183 sites in United States, Australia and 16 more
- Volunteers
- 1,401 people
- Sponsor
- Hoffmann-La Roche
Lymphoma
A Study to Evaluate Glofitamab as a Single Agent vs. Investigator's Choice in Participants With Relapsed/Refractory Mantle Cell Lymphoma
The purpose of this study is to evaluate the efficacy of glofitamab monotherapy compared with an investigator's choice of either rituximab plus bendamustine (BR), or lenalidomide with rituximab (R-Len) in patients with relapsed…
- Trial name
- GLOBRYTE (NCT06084936)
- Testing
- Obinutuzumab, Glofitamab, Rituximab
- Where
- 83 sites in United States, Australia and 11 more
- Volunteers
- 182 people
- Sponsor
- Hoffmann-La Roche
Chronic Lymphocytic Leukemia, Small Lymphocytic Lymphoma
A Study of BGB-16673 Compared to Investigator's Choice in Participants With Relapsed/Refractory Chronic Lymphocytic Leukemia or Small Lymphocytic Lymphoma Previously Exposed to Covalent Bruton Tyrosine Kinase (BTK) Inhibitors
The purpose of this study is to investigate the efficacy and safety of BGB-16673 compared with investigator's choice (bendamustine plus rituximab or high-dose methylprednisolone plus rituximab or chlorambucil plus obinutuzumab)…
- Trial name
- CaDAnCe-303 (NCT06970743)
- Testing
- BGB-16673, Bendamustine, Rituximab
- Where
- 56 sites in China, Taiwan
- Volunteers
- 153 people
- Sponsor
- BeOne Medicines
Non-Hodgkin's Lymphoma, Mantle Cell Lymphoma
Clinical Study on SyB L-0501 in Patients With Indolent B-cell Non-Hodgkin's Lymphoma or Mantle Cell Lymphoma
The purpose of this study is to assess the antitumor effects and safety of bendamustine hydrochloride (SyB L-0501) in patients with indolent B-cell non-Hodgkin's lymphoma or mantle cell lymphoma.
- Trial name
- NCT00612183
- Testing
- bendamustine hydrochloride
- Where
- 17 sites in Japan
- Volunteers
- 56 people
- Sponsor
- SymBio Pharmaceuticals
Follicular Lymphoma (FL), Non Hodgkin Lymphoma
Phase 3 Study of Zandelisib (ME-401) in Combination With Rituximab in Patients With iNHL - (COASTAL)
This is a Phase 3 study of the PI3Kδ inhibitor Zandelisib (ME-401) in combination with rituximab, in comparison to standard immunochemotherapy (Rituximab-Bendamustine or Rituximab-CHOP) in subjects with relapsed or refractory FL…
- Conditions
- Follicular Lymphoma (FL), Non Hodgkin Lymphoma, Marginal Zone Lymphoma
- Trial name
- NCT04745832
- Testing
- Zandelisib, Rituximab, Bendamustine
- Where
- 141 sites in United States, Australia and 17 more
- Volunteers
- 82 people
- Sponsor
- MEI Pharma, Inc.
Diffuse Large B-cell Lymphoma Refractory, Follicular B-cell Non-Hodgkin's Lymphoma
Study of Rituximab and Bendamustine With or Without Brentuximab Vedotin for CD30 Positive Diffuse Large B-cell Lymphoma
This is a randomized, open-label, multicenter, Phase 2 clinical trial designed to evaluate the efficacy and safety of brentuximab vedotin in combination with rituximab and bendamustine for the treatment of patients with relapsed…
- Trial name
- NCT02594163
- Testing
- Brentuximab Vedotin, Rituximab, Bendamustine
- Where
- 50 sites in United States, Czechia and 5 more
- Volunteers
- 25 people
- Sponsor
- Seagen Inc.
Chronic Lymphocytic Leukemia
Study of Acalabrutinib (ACP-196) in Combination With Venetoclax (ABT-199), With and Without Obinutuzumab (GA101) Versus Chemoimmunotherapy for Previously Untreated CLL
The purpose of this study is to evaluate the efficacy and safety of acalabrutinib in combination with venetoclax and acalabrutinib in combination with venetoclax with and without obinutuzumab compared to chemoimmunotherapy in…
- Trial name
- AMPLIFY (NCT03836261)
- Testing
- Acalabrutinib, Venetoclax, Chemoimmunotherapy
- Where
- 169 sites in United States, Argentina and 25 more
- Volunteers
- 984 people
- Sponsor
- Acerta Pharma BV
Diffuse Large B Cell Lymphoma, Transformed Indolent Non-Hodgkin's Lymphoma
FT596 in Combination With R-CHOP in Subjects With B-Cell Lymphoma
This is a Phase I study of FT596 in combination with two different schedules (standard or alternate) of R-CHOP in subjects with B-cell lymphoma who are previously untreated or have received no more than one prior line of…
- Conditions
- Diffuse Large B Cell Lymphoma, Transformed Indolent Non-Hodgkin's Lymphoma, Follicular Lymphoma, Mantle Cell Lymphoma
- Trial name
- NCT05934097
- Testing
- FT596, Cyclophosphamide, Doxorubicin
- Sponsor
- Fate Therapeutics
Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma
A Study of DZD8586 Versus Investigator's Choice in r/r CLL/SLL (TAI-SHAN6)
This is a phase 3, open-label, randomized, multi-center study assessing the efficacy and safety of DZD8586 versus investigator's choice in participants with chronic lymphocytic leukemia/small lymphocytic lymphoma who have…
- Trial name
- NCT07139873
- Testing
- DZD8586, Bendamustine, Idelalisib
- Where
- 2 sites in China
- Volunteers
- 250 people
- Sponsor
- Dizal Pharmaceuticals